Earnings ·
Azitra, Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $3.3 million…
AZTRAzitra, Inc.
Azitra, Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $3.3 million compared to $2.9 million in the prior year period. Research and development expenses remained flat at $1.4 million, while general and administrative expenses increased to $2.1 million from $1.5 million. The company held $6.7 million in cash and cash equivalents as of June 30, 2026. Operationally, Azitra announced positive preclinical data for ATR-COSF supporting advancement toward a proof-of-concept clinical study, continued enrollment in the Phase 1/2 trial for ATR-04 with topline data expected in Q4 2026, and plans to pause further enrollment in the ATR-12 Netherton syndrome study. Azitra is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and novel products across therapeutics, cosmeceuticals, and biotechnology applications.